Partnering Opportunities at RESI Boston: Platform Opens August 19 

15 Aug

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti

As RESI Boston approaches, excitement is building for this hybrid conference taking place on September 25 at The Westin Copley Hotel, followed by virtual partnering on September 26-27. The partnering platform will open on August 19, allowing attendees to schedule both in-person and virtual meetings.

What distinguishes RESI is its focus on the life sciences sector. The Life Science Nation (LSN) Partnering Platform facilitates connections between startups and investors through a curated environment. Unlike traditional conferences where information about potential partners is limited, RESI provides detailed profiles derived from personal interviews with investors in the LSN network. This ensures that startups can engage with investors who are genuinely interested in their specific sector and stage of development.

The platform allows startups to filter their search based on various criteria, enabling efficient identification of the right investors. However, success in partnering requires proactive engagement. Companies that excel typically send over 100 meeting requests and follow up consistently, making a strong effort to establish connections.

To assist attendees, RESI will offer a free partnering tutorial next week, providing strategies to maximize their time at the conference:

  • Thursday, August 22, 2024 1:00 PM-2:00 PM – Partnering Tutorial – Sign Up

As the partnering platform opens on August 19, startups should prepare early by crafting a thoughtful strategy and sending out meeting requests promptly. With the insights gained from the tutorial, attendees can enhance their chances of forming valuable partnerships.

In summary, RESI Boston is a unique opportunity for life science startups to connect with investors who can help propel their projects forward. Mark your calendars for August 19 and get ready to unlock new possibilities at RESI Boston.

RESI-Boston-2024-September-1100pxw

Register-now-button-new

Hot Investor Profile: New Venture Fund Invests in Early-Stage Therapeutics Companies in North America, Europe, and Israel

15 Aug

A newly established venture fund is currently fundraising for their newest fund and actively pursuing new investment opportunities that they can invest through their new fund. Typical check size is $2-5M, and the firm invests exclusively in therapeutics. The firm focuses on opportunities based in North America, Europe, and Israel. About 20% of their investments to date have been in Europe and Israel, while the rest have been in North America-based companies. 
 
The firm invests exclusively in therapeutics companies, and does not pursue medical devices, diagnostics, or digital health opportunities at this time. Within therapeutics, the firm is most interested in advanced therapeutics including genetic diseases, oncology/immuno-oncology, autoimmune, cardiovascular, ophthalmology, fibrosis, and rare/orphan diseases. The firm is least interested in neurodegenerative, infectious diseases, oligonucleotide, and epigenetic drugs, and does not consider reformulated or repurposed drugs. In terms of stage of development, the firm’s sweet spot is between late pre-clinical stage (after animal data) and Phase II. 
 
The firm seeks to invest in technologies backed by strong IP protection. To date, the firm has mostly led or co-led investment rounds, prefers to take an active stance in their portfolio companies, and requires a board seat. However, the firm is open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Corporate Venture Fund of Large Pharmaceutical Seeks Global Opportunities in Therapeutics and Platform Technologies

15 Aug

A strategic corporate venture fund of a global pharmaceutical company actively invests in early-stage biotech companies that are of strategic interest to the parent pharmaceutical. The firm invests in global opportunities, but focuses primarily on North America and Europe. 
 
The firm invests in early-stage therapeutics and platform technology companies. The firm’s main areas of interest include immunology and inflammation, kidney disease including transplant, serious diseases treated in hospitals, neurodegenerative disease, and rare disease. Regarding platform technologies, the firm is interested in drug discovery technologies for small molecule, peptide, nucleic acid, and other novel modalities, delivery systems (CNS, kidney disease), and cell therapies (excluding those targeting oncology). The firm invests primarily in pre-clinical opportunities, and can consider those as early as discovery stage. The firm does not actively seek opportunities in medical devices, diagnostics, or digital health at this time. 
 
The firm has no specific company or management team requirements. The firm can help support companies beyond capital. The firm can offer scientific expertise, and is able to collaborate on early stage proof-of-concept experiments and projects with emerging companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Europe-Based VC Firm With New Fund Invests in Digital Health, AI-Enabled Medtech, and Other Digital Technologies

15 Aug

A venture capital firm with offices in Western Europe is currently making investments out of its newest fund that had an initial close recently. The firm looks to make equity investments into early stage companies up to €4M, with a focus on Seed to Series A investment rounds. The firm is actively reviewing new opportunities, with a focus in Europe. About 5-10% of the investments will be made in the US. 
 
With the newest fund, the firm is looking for technologies leveraging AI, digital therapeutics, and digital health platforms (i.e. data aggregation). The firm will consider medical device or diagnostics applications that have a AI component, but is most interested in investing in digital health. The firm is open to investing in companies in the earliest stages of development, pre-pilot. 
 
The firm is looking for privately held companies with experienced management teams. The firm is very open to working with incomplete management teams to help them fill out any gaps in management. The firm looks to be a strong value adding investor providing companies with its access to its network of other investors and strategic partners as well. The firm prefers to act as a lead or co-lead, especially in companies based in Spain, but will prefer to syndicate in opportunities outside of Europe. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Impact-Driven Venture Fund Invests in Pre-Seed to Series A Digital Health Software Startups Across Europe

15 Aug

An impact-driven venture fund with offices in US and Europe focuses on investments that improve the quality of Life and wellbeing of individuals and for medium and long-term relief of the ever-increasing strain on (public) healthcare, social welfare, and the planet. The firm invests in tech startups using Emerging & Disruptive Technologies (AI, Data, Blockchain, Iot,  AR/VR, and Digital Security) to solve social and environmental challenges within the 4 following SDGs: Health & Wellbeing, Quality Education, Sustainable City and Climate Action. The firm participates in Pre-Seed to Series A rounds with Seed being their sweet spot. The Fund invests across Europe. The firm also has an excellent coaching program to support its portfolio teams. 
 
In terms of Healthcare, the firm is interested in digital health software that helps with disease prevention, optimized recovery and improved quality of life. The firm purely invests in software and is not interested in hardware or devices. 
 
The firm does not have specific company requirements. The firm can act as a (co)lead investor and typically takes a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Family Office BioForum at RESI Boston Sept 25: Family Office Fund Managers Deliver Keynotes 

8 Aug

By Dennis Ford, Founder and CEO of Life Science Nation

Life Science Nation is proud to announce the upcoming Global Family Office BioForum, which will take place on Wednesday, September 25th, at the Westin Copley Place in Back Bay, Boston, as part of the renowned RESI program. This unique event will feature an open-to-the-public Family Office Panel and an exclusive invitation-only Global Family Office BioForum (GFOB) luncheon, where key figures from prominent family offices will discuss critical insights into the life sciences investment landscape.

The luncheon keynote session will spotlight three influential leaders:

michael-langerMichael Langer
Co-founder & Managing Partner at T.Rx Capital		 Sunil-ShahSunil Shah
Co-founder of the o2h Group and CEO of o2h Ventures		 John-ParkerJohn Parker
Family Member and Trustee of the Charles Hood Foundation and Founder of Springhood Ventures

Together, they will delve into the theme of “Leveraging Life Science Domain Expertise, Family Office Networks, to Impact Early-Stage Companies,” highlighting their current initiatives and strategies within the life science sector.

The demand for early-stage capital is increasingly critical as the life sciences field continues flourishing with innovative discoveries and cutting-edge technologies. The Global Family Office BioForum (GFOB) is a key platform where family offices can identify promising startups and collaborate with other like-minded investors.

If you are a Family Office and would like to attend the Family Office BioForum Luncheon
Apply Here
August 20, Family Office Webinar – Free Sign Up
1 PM Investor Fireside Chat – Strategies for Family Office Investments
– Katherine Hill Ritchie, Founder, Private Capital Investments, LLC
– Ron Paliwoda, Founder and President, Paliwoda Group
– Shubhra Jain, Principal, Head of Healthcare Investments, Tarsadia Investments
September 25, RESI Boston 2024
Global Family Office BioForum (GFOB) Luncheon
12 PM Welcome / Opening Remarks
– Dennis Ford, Founder & CEO, Life Science Nation
– Claire Jeong, VP of Investor Research, Asia BD, Life Science Nation
12:05 PM Panel Discussion “Leveraging Life Science Domain Expertise, Family Office Networks, to Impact Early-Stage Companies”
– Michael Langer, Co-Founder & Managing Partner, T.Rx Capital
– Sunil Shah, Co-Founder of o2h Group; CEO of o2h Ventures
– John Parker, Founder of Springhood Ventures
12:40 PM Networking
Family Office Investors Panel  
3 PM Perspectives on Early Stage Investments
– Michael Langer, Co-Founder & Managing Partner, T.Rx Capital
– Sunil Shah, Co-Founder of o2h Group; CEO of o2h Ventures
– John Parker, Founder Springhood Ventures
– John Abeles, General Partner, Northlea Partners
– David Prim, Senior Associate, Broadview Ventures

The Power of Syndication

Syndication is a vital investment strategy that benefits family offices and entrepreneurs. By collaborating with other investors, family offices can diversify their risk, streamline due diligence processes, access a more comprehensive array of investment opportunities, and leverage combined expertise. For entrepreneurs, the advantages are equally substantial; they gain access to a syndicate’s collective knowledge and resources, significantly enhancing their fundraising efforts and increasing their chances of securing the essential funds needed for growth.

 The Family Office Factor

Family offices are distinguished by their long-term investment horizons and dedication to generating meaningful impact. With a mission to preserve and grow wealth for future generations, these entities are uniquely suited to contribute to the life sciences sector. Their involvement transcends mere financial support, offering mentorship, guidance, and a genuine commitment to the success of the ventures they back. The Global Family Office BioForum (GFOB) recognizes and amplifies this unique role, creating an environment where family offices can forge connections with like-minded syndicate partners and explore transformative investment opportunities.

Innovations in Neuromuscular Disease

8 Aug

Interview with Dr. Sharon Hesterlee, Executive Vice President and Chief Research Officer at Muscular Dystrophy Association (MDA) By Caitlin Dolegowski, Marketing Manager, LSN

Sharon-HesterleeDr. Sharon Hesterlee
 CaitiCaitlin Dolegowski

Today, we are excited to feature Dr. Sharon Hesterlee, Executive Vice President and Chief Research Officer at the Muscular Dystrophy Association (MDA), a title sponsor at our upcoming RESI Boston conference. Dr. Hesterlee plays a vital role in advancing research and treatment for neuromuscular diseases. In this interview, she discusses MDA’s investment programs, including the MOVR Data Hub and Venture Philanthropy, and shares insights on supporting biotech startups, key criteria for funding ultra-rare disease therapies, and emerging trends in research. Join us as Dr. Hesterlee offers valuable advice for entrepreneurs seeking to make an impact in the neuromuscular disease landscape.

RESI-Boston-2024-September-1100pxw

RESI-London-2024-1100px

RESI-SF-2025-Banner-1100px

← Older Entries
Newer Entries →